Healthcare Facilities company Healthcare Global Enterprises announced Q1FY26 results Revenue stood at Rs 6,132 million a growth of 17% YoY, driven by strong performance across key geographies including Ahmedabad, Kolkata, Nagpur and Mumbai. Adj. EBIDTA stood at Rs 1,118 million (20% YoY growth) with 18.2% EBITDA margin for Q1FY26 compared to Rs 929 million with 17.7% EBITDA margin in Q1FY25. Margin improvement driven by operating leverage in Emerging centers and continuous efforts in improving cost efficiencies. OPD Volumes grew by 17% compared to same period last year and InPatient bed occupancy stood at 62% in Q1FY26 compared to 61% in Q1FY25 despite operationalizing 219 additional beds. LINAC capacity utilization on a like for like basis (i.e. for 36 LINACs) stood at 69% for Q1FY26 compared to 65% in Q1FY25. Overall ARPOB stood at Rs 44,751 vs. Rs 44,342 in Q1FY25, a growth of 0.9%. Change in service mix for the quarter has led to increase in ALOS, thereby impacting ARPOB. PAT for the quarter stood at Rs 47.3 million compared to Rs 120.8 million. Lower PAT on account of higher depreciation and interest expense from growth investments and acquisitions undertaken in the last year. RoCE for established centers stood at 17.3% compared to 18.4% in Q1FY25. The marginal decline is attributed to investments made towards expansion in Ahmedabad. Pre-corporate allocations, RoCE was 26.1%. B.S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises. said: “HCG continues to be on a strong growth trajectory, anchored by its leadership in cancer care, trusted brand, and commitment to clinical excellence. We remain focused on pioneering advanced technologies in India, including Cyclotron, Adaptive RT, CyberKnife, and AI-driven systems, while expanding capabilities in genomics and proteomics. Our integrated, multidisciplinary approach ensures that patients receive the right treatment the first time across our growing network. With a solid foundation in place and a promising future ahead, I am pleased to welcome Dr. Manish Mattoo as our new Executive Director and Chief Executive Officer. The Board is confident that his proven leadership, strategic acumen, and healthcare experience will be instrumental in shaping HCG’s next phase of growth and driving long-term value for all stakeholders.” Manish Mattoo, CEO HealthCare Global Enterprises, added: “HCG has long stood as a beacon of excellence in cancer care, consistently setting new benchmarks in clinical innovation and outcomes. At the core of this success is its world-class team of oncologists, surgeons, and specialists, supported by a deeply ingrained culture of multidisciplinary collaboration and cutting-edge technology. With a strong pan-India presence built over more than two decades, HCG ensures that high-quality and advanced cancer care is accessible to patients across the country. Clinically, HCG delivers consistent outcomes across its network, with performance metrics that are on par with some of the most reputed oncology centers in the world. I am honored to join HCG, and it is a privilege to lead an organization that is transforming cancer care in India. I look forward to working closely with our teams to build on this remarkable legacy and drive the next phase of growth, innovation, and impact.” Result PDF
Conference Call with Healthcare Global Enterprises Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.